Search

Your search keyword '"Rodriguez-Antolin A"' showing total 188 results
Start Over Author "Rodriguez-Antolin A" Language english
188 results on '"Rodriguez-Antolin A"'

3. Molecular diagnosis of cystic fibrosis by RNA obtained from nasal epithelial cells

Author

Prior-de Castro, Carmen, Martínez Gallego, Miguel Ángel, Gómez-González, Clara, de Sancho Martín, Rubén, Rodríguez-Antolín, Carlos, Rodríguez-Jiménez, Carmen, del Pozo Mate, Ángela, Zamarrón de Lucas, Ester, Ruiz de Valbuena Maiz, Marta, de Manuel Gómez, Cristina, Alcolea Batres, Sergio, Prados Sánchez, María Concepción, and J Torres, Rosa

Published
2024
Full Text
View/download PDF

5. Transplant renal artery stenosis: Study of incidence using doppler ultrasound, risk factors and analysis is effect in graft outcomes

Author

Calzas Montalvo, C., Medina-Polo, J., Miranda Utrera, N.R., Juste Álvarez, S., de la Calle Moreno, A., Caro González, M.P., Santos Perez de la Blanca, R., Hernández Arroyo, M., Peña Vallejo, E., Teigell Tobar, J., Duarte Ojeda, J.M., Pamplona Casamayor, M., Tejido Sánchez, Á., García González, L., Arrébola Pajares, A., Sánchez Guerrero, Á., Rodríguez de la Calle, J., and Rodríguez Antolín, A.

Published
2024
Full Text
View/download PDF

8. European Association of Urology biochemical recurrence risk groups after radical prostatectomy: External validation and identification of independent risk factors for progression and death

Author

Sopeña Sutil, R., Vázquez-Martul, D., De Pablos-Rodríguez, P., Peña Vallejo, E., Altez Fernández, C., Gómez-Ferrer Lozano, A., Téigell Tobar, J., Rollón Prieto, G., Coy García, A., Ramírez Backhaus, M., Chantada Abal, V., and Rodríguez Antolín, A.

Published
2023
Full Text
View/download PDF

14. Holmium laser enucleation of the prostate (HoLEP) vs. Superpulsed Thulium laser (TFL) and Aquablation (Aqua) in men with benign prostatic hyperplasia related obstructive symptoms: A Randomized Clinical Trial.

Author

J. Romero-Otero, A.R.J. Rodriguez Antolin, J.J.Q. Justo Quintas, B.G.G. García Gómez, F. Lista Mateos, and E.G.G. Esther

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2023
Full Text
View/download PDF

17. The SEQC2 epigenomics quality control (EpiQC) study

Author

Jonathan Foox, Jessica Nordlund, Claudia Lalancette, Ting Gong, Michelle Lacey, Samantha Lent, Bradley W. Langhorst, V. K. Chaithanya Ponnaluri, Louise Williams, Karthik Ramaswamy Padmanabhan, Raymond Cavalcante, Anders Lundmark, Daniel Butler, Christopher Mozsary, Justin Gurvitch, John M. Greally, Masako Suzuki, Mark Menor, Masaki Nasu, Alicia Alonso, Caroline Sheridan, Andreas Scherer, Stephen Bruinsma, Gosia Golda, Agata Muszynska, Paweł P. Łabaj, Matthew A. Campbell, Frank Wos, Amanda Raine, Ulrika Liljedahl, Tomas Axelsson, Charles Wang, Zhong Chen, Zhaowei Yang, Jing Li, Xiaopeng Yang, Hongwei Wang, Ari Melnick, Shang Guo, Alexander Blume, Vedran Franke, Inmaculada Ibanez de Caceres, Carlos Rodriguez-Antolin, Rocio Rosas, Justin Wade Davis, Jennifer Ishii, Dalila B. Megherbi, Wenming Xiao, Will Liao, Joshua Xu, Huixiao Hong, Baitang Ning, Weida Tong, Altuna Akalin, Yunliang Wang, Youping Deng, and Christopher E. Mason

Subjects
Biology (General), QH301-705.5, Genetics, QH426-470
Abstract

Abstract Background Cytosine modifications in DNA such as 5-methylcytosine (5mC) underlie a broad range of developmental processes, maintain cellular lineage specification, and can define or stratify types of cancer and other diseases. However, the wide variety of approaches available to interrogate these modifications has created a need for harmonized materials, methods, and rigorous benchmarking to improve genome-wide methylome sequencing applications in clinical and basic research. Here, we present a multi-platform assessment and cross-validated resource for epigenetics research from the FDA’s Epigenomics Quality Control Group. Results Each sample is processed in multiple replicates by three whole-genome bisulfite sequencing (WGBS) protocols (TruSeq DNA methylation, Accel-NGS MethylSeq, and SPLAT), oxidative bisulfite sequencing (TrueMethyl), enzymatic deamination method (EMSeq), targeted methylation sequencing (Illumina Methyl Capture EPIC), single-molecule long-read nanopore sequencing from Oxford Nanopore Technologies, and 850k Illumina methylation arrays. After rigorous quality assessment and comparison to Illumina EPIC methylation microarrays and testing on a range of algorithms (Bismark, BitmapperBS, bwa-meth, and BitMapperBS), we find overall high concordance between assays, but also differences in efficiency of read mapping, CpG capture, coverage, and platform performance, and variable performance across 26 microarray normalization algorithms. Conclusions The data provided herein can guide the use of these DNA reference materials in epigenomics research, as well as provide best practices for experimental design in future studies. By leveraging seven human cell lines that are designated as publicly available reference materials, these data can be used as a baseline to advance epigenomics research.

Published
2021
Full Text
View/download PDF

27. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry

Author

Pórtela, P., Blanco, E., González, J.A., Baena, V., Morales, P., Villavicencio, H., Palou, J., Loizaga, A., Ciudin, A., Mihai, D., Martínez Jabaloyas, J.M., Castelló, A., Díez, N., Romero, F.J., Subirá, J., Chávez, A.I., Capapé, V., Mata, M., Elizalde, J., Lobato, J.J., Jiménez, J., Pérez Llorca, L., Tenza, J.A., Herranz, F., Husillos, A., López, E., Ramírez, D., Blaha, I., Izquierdo, E., Reina, L., Passas, J., Díez, L., Hevia, M.A., Castells, M., Concepción Masip, T., Plata, A.C., Asuar Aydillo, S., Alonso, J., Mateos, J., Carballido, J., Martínez, C., Areche, J., Rodríguez, R., Hevia, V., Álvarez, S., Requena, M.J., Prieto, R., Carazo, J.L., Márquez, J., Gómez, E., García, J.H., Amón, J., Cepeda, M., Álvarez, L., Rodríguez, V., de la Cruz, B., Rivero, A., Sánchez, J.F., Mainez, J.A., Medina, R., Conde, M., Castiñeiras, J., González Baena, A.C., Sánchez, E., Campanario, R., Saiz, R., Romero, E., Morote, J., Raventós, C.X., Celma, A., Vázquez, F., Gómez, A., Buendía, E., García, N., Garcia-Rodriguez, J., Fernandez-Gomez, J.M., Cozar, J.M., Miñana, B., Gomez-Veiga, F., and Rodriguez-Antolin, A.

Published
2020
Full Text
View/download PDF

28. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study

Author

Matsubara, Nobuaki, Chi, Kim N., Özgüroğlu, Mustafa, Rodriguez-Antolin, Alfredo, Feyerabend, Susan, Fein, Luis, Alekseev, Boris Y., Sulur, Giri, Protheroe, Andrew, Li, Susan, Mundle, Suneel, De Porre, Peter, Tran, Namphuong, and Fizazi, Karim

Published
2020
Full Text
View/download PDF

29. Author Correction: The SEQC2 epigenomics quality control (EpiQC) study

Author

Foox, Jonathan, Nordlund, Jessica, Lalancette, Claudia, Gong, Ting, Lacey, Michelle, Lent, Samantha, Langhorst, Bradley W., Ponnaluri, V. K. Chaithanya, Williams, Louise, Padmanabhan, Karthik Ramaswamy, Cavalcante, Raymond, Lundmark, Anders, Butler, Daniel, Mozsary, Christopher, Gurvitch, Justin, Greally, John M., Suzuki, Masako, Menor, Mark, Nasu, Masaki, Alonso, Alicia, Sheridan, Caroline, Scherer, Andreas, Bruinsma, Stephen, Golda, Gosia, Muszynska, Agata, Łabaj, Paweł P., Campbell, Matthew A., Wos, Frank, Raine, Amanda, Liljedahl, Ulrika, Axelsson, Tomas, Wang, Charles, Chen, Zhong, Yang, Zhaowei, Li, Jing, Yang, Xiaopeng, Wang, Hongwei, Melnick, Ari, Guo, Shang, Blume, Alexander, Franke, Vedran, de Caceres, Inmaculada Ibanez, Rodriguez-Antolin, Carlos, Rosas, Rocio, Davis, Justin Wade, Ishii, Jennifer, Megherbi, Dalila B., Xiao, Wenming, Liao, Will, Xu, Joshua, Hong, Huixiao, Ning, Baitang, Tong, Weida, Akalin, Altuna, Wang, Yunliang, Deng, Youping, and Mason, Christopher E.

Published
2021
Full Text
View/download PDF

32. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Author

Fizazi, Karim, Tran, NamPhuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez-Antolin, Alfredo, Alekseev, Boris Y, Özgüroğlu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, Sulur, Giri, Luna, Yesenia, Li, Susan, Mundle, Suneel, and Chi, Kim N

Published
2019
Full Text
View/download PDF

33. Kidney transplant from uncontrolled donation after circulatory death donors maintained by nECMO has long-term outcomes comparable to standard criteria donation after brain death

Author

Molina, María, Guerrero-Ramos, Félix, Fernández-Ruiz, Mario, González, Esther, Cabrera, Jimena, Morales, Enrique, Gutierrez, Eduardo, Hernández, Eduardo, Polanco, Natalia, Hernández, Ana, Praga, Manuel, Rodriguez-Antolín, Alfredo, Pamplona, Manuel, de la Rosa, Federico, Cavero, Teresa, Chico, Mario, Villar, Alicia, Justo, Iago, and Andrés, Amado

Published
2019
Full Text
View/download PDF

36. MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species

Author

Vera-Puente, Olga, Rodriguez-Antolin, Carlos, Salgado-Figueroa, Ana, Michalska, Patrycja, Pernia, Olga, Reid, Brett M., Rosas, RocÍo, Garcia-Guede, Alvaro, SacristÁn, Silvia, Jimenez, Julia, Esteban-Rodriguez, Isabel, Martin, M. Elena, Sellers, Thomas A., León, Rafael, Gonzalez, VÍctor M., De Castro, Javier, and Ibanez de Caceres, Inmaculada

Published
2018
Full Text
View/download PDF

40. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

Author

Chi, Kim N, Protheroe, Andrew, Rodríguez-Antolín, Alfredo, Facchini, Gaetano, Suttman, Henrik, Matsubara, Nobuaki, Ye, Zhangqun, Keam, Bhumsuk, Damião, Ronaldo, Li, Tracy, McQuarrie, Kelly, Jia, Bin, De Porre, Peter, Martin, Jason, Todd, Mary B, and Fizazi, Karim

Published
2018
Full Text
View/download PDF

41. Dietary sucrose regulates the expression of the Cd36 gene in hepatic tissue of rats with obesity and Non Alcoholic Fatty Liver Disease (NAFLD)

Author

Rodolfo Quintana Castro, Ida Soto Rodriguez, Rosa A. Deschamps Lago, Peter Grube Pagola, Jorge Rodriguez Antolin, Adriana Peres Quintal, Jaime Rivera Rivera, and Alfonso Alexander Aguilera

Subjects
fatty liver, metabolic syndrome, sucrose, cd36, insulin resistance, obesity, Medicine
Abstract

Aim: To evaluate the mRNA expression levels of Cd36 in adipose and hepatic tissues, in rats with NAFLD after the consumption of sucrose for 10 and 20 weeks. Methods: Twenty Wistar rats, all nearly 21 days old were divided into two experimental groups (NAFLD-10 and NAFLD-20), that received a standard diet (2014 Teklad Global) plus 30% sucrose in their drinking water for 10 and 20 weeks and the control groups (C Groups). Variables such as body weight, food intakes, and serum parameters were measured. Adipose and hepatic tissues were extirpated; some tissue was preserved in formalin and some at -70 °C until analysis. Histological analysis was carried out, and the Cd36 mRNA expression levels were determined. Results: The rats in the NAFLD-10 and NAFLD-20 groups showed a significative increase in abdominal fat, triglycerides, free fatty acids, insulin, AST, ALT, uric acid and HOMA index; as well as changes in the cellular dynamics in adipose tissue, (adipocytes hypertrophic: >1500 µm2) with respect to the control groups (P

Published
2018
Full Text
View/download PDF

42. An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells

Author

Olga Vera, Carlos Rodriguez-Antolin, Javier de Castro, Florian A. Karreth, Thomas A. Sellers, and Inmaculada Ibanez de Caceres

Subjects
lncrna, dna methylation, cisplatin-resistance, lung/ovarian cancer, Genetics, QH426-470
Abstract

Long noncoding RNAs (lncRNAs) are critical regulators of cell biology whose alteration can lead to the development of diseases such as cancer. The potential role of lncRNAs and their epigenetic regulation in response to platinum treatment are largely unknown. We analyzed four paired cisplatin-sensitive/resistant non-small cell lung cancer and ovarian cancer cell lines. The epigenetic landscape of overlapping and cis-acting lncRNAs was determined by combining human microarray data on 30,586 lncRNAs and 20,109 protein coding mRNAs with whole-genome bisulfite sequencing. Selected candidate lncRNAs were further characterized by PCR, gene-ontology analysis, and targeted bisulfite sequencing. Differential expression in response to therapy was observed more frequently in cis-acting than in overlapping lncRNAs (78% vs. 22%, fold change ≥1.5), while significantly altered methylation profiles were more commonly associated with overlapping lncRNAs (29% vs. 8%; P value

Published
2018
Full Text
View/download PDF

47. Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy

Author

Rosas-Alonso, Javier Guijarro-Eguinoa, Sara Arjona-Hernandez, Stefan Stewart, Olga Pernia, Pedro Arias, Itsaso Losantos-García, Tania Rubio, Miranda Burdiel, Carlos Rodriguez-Antolin, Patricia Cruz-Castellanos, Oliver Higuera, Alberto M. Borobia, Sonia Rodriguez-Novoa, Javier de Castro-Carpeño, Inmaculada Ibanez de Caceres, and Rocio

Subjects
pharmacogenetics, platinum resistance, cisplatin, carboplatin, non-small cell lung cancer, DPYD
Abstract

Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major obstacle in successful treatment. In this study, we aimed to investigate the impact of several pharmacogenetic variants in patients with unresectable NSCLC treated with platin-based chemotherapy. Our results showed that DPYD variant carriers had significantly shorter progression-free survival and overall survival compared to DPYD wild-type patients, whereas DPD deficiency was not associated with a higher incidence of high-grade toxicity. For the first time, our study provides evidence that DPYD gene variants are associated with resistance to platin-based chemotherapy in NSCLC patients. Although further studies are needed to confirm these findings and explore the underlying mechanisms of this association, our results suggest that genetic testing of DPYD variants may be useful for identifying patients at a higher risk of platin-based chemotherapy resistance and might be helpful in guiding future personalized treatment strategies in NSCLC patients.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results